Citation

Schaft N. Cancers (Basel) 2020; 12(9): 1-36.

Copyright

(Copyright © 2020, MDPI: Multidisciplinary Digital Publications Institute)

DOI

10.3390/cancers12092567

PMID

unavailable

Abstract

CAR-T cells showed great potential in the treatment of patients with hematologic tumors. However, the clinical efficacy of CAR-T cells against solid tumors lags behind. To obtain a comprehensive overview of the landscape of CAR-T cell clinical trials against this type of cancer, this review summarizes all the 196 studies registered at clinicaltrials.gov. Special focus is on: (1) geographical distribution; (2) targeted organs, tumor entities, and antigens; (3) CAR transfer methods, CAR formats, and extra features introduced into the T cells; and (4) patient pretreatments, injection sites, and safety measurements. Finally, the few data on clinical outcome are reported. The last assessment of clinicaltrials.gov for the data summarized in this paper was on 4 August 2020. © 2020 by the author. Licensee MDPI, Basel, Switzerland.

Language: en

Keywords

human; Review; multiple organ failure; safety; mortality; fatigue; tachycardia; neutropenia; thrombocytopenia; headache; nonhuman; diarrhea; leukopenia; hypotension; heart arrest; fever; lymphocytopenia; rash; neurologic disease; anemia; myalgia; dyspnea; protein expression; nausea and vomiting; Clinical trial; disseminated intravascular clotting; adult respiratory distress syndrome; chill; lung toxicity; clinical outcome; CAR format; CAR transfer; CAR-T cell; chimeric antigen receptor; chimeric antigen receptor T-cell immunotherapy; Clinicaltrials.gov; cytokine release syndrome; solid malignant neoplasm; Solid tumor; Suicide switch; T lymphocyte subpopulation; Tumor antigen; tumor associated leukocyte